INDICES

You have the enormous burden of absorbing datapoints and perceptions from all directions and synthesizing those insights into a tangible strategy. Leverage the Oncology Index and Biologics Index to gain a single source of truth.

Support your strategy with unblinded organization names for optimal action and forward-looking analysis on payer trends, oncology and non-oncology management, and disruptive market events.

2020 Managed Care Biologics & Injectables: General Access Management Topics

Q1
  • Payer Management Priorities / Unmet Needs
  • Identified Drivers of Cost
  • Copay Accumulator and Maximizer
  • Step Therapy Legislation Medicare Part B
  • Items in the News Throughout the Year
Q2
  • Administrative Burden
  • Site of Care Dynamics
  • IDN Dynamics
Q3
  • Physician Reimbursement
  • Pharmacy / Medical / Comprehensive Deductibles
  • SPP / PBM / Hospital Utility, Distribution, & Contracting
Q4
  • Impact of Patient Cost Sharing
  • Patient Assistance / Copay Programs
  • Patient Pre-Treatment Qualification

TA-Specific Deep Dives

Q1
  • Orphan Drug Overview / Gaucher’s / HAE / Growth Hormone / SMA
  • Migraine
  • Seizures
  • Rheumatoid Arthritis
  • Multiple Sclerosis
Q2
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Severe Asthma
  • Diabetes
Q3
  • Ulcerative Colitis/Crohn’s Disease
  • Hypercholesterolemia
  • Gene Therapy
  • Sleep
Q4
  • Hemophilia
  • Immunodeficiency
  • AMD / RVO / DME
  • NASH

2020 Managed Care Oncology: General Access Management Topics

Q1
  • Payer Management Priorities/Unmet Needs
  • Identified Drivers of Cost
  • Copay Accumulator and Maximizer
  • Step Therapy Legislation Medicare Part B
  • Oncology Care Model/MACRA
  • Items in the News Throughout the Year 
Q2
  • Administrative Burden
  • Site of Care Dynamics
  • IDN Dynamics
Q3
  • Physician Reimbursement
  • Pharmacy/Medical/ Comprehensive Deductibles
  • Clinical Treatment Pathways
  • SPP/PBM/Hospital Utility, Distribution, & Contracting
Q4
  • Impact of Patient Cost Sharing
  • Patient Assistance/Copay Programs
  • Patient Pre-Treatment Qualification

TA-Specific Deep Dives

Q1
  • Breast Cancer
  • Metastatic Melanoma
  • NSCLC
  • Bladder Cancer
Q2
  • Neutropenia
  • ESAs
  • ALL/CLL/NHL/AML/MCL
  • Biomarker Driven Oncology Drugs
Q3
  • Prostate Cancer
  • Multiple Myeloma
  • Ovarian Cancer
  • CAR-T
Q4
  • Renal Cell Carcinoma
  • Liver Cancer
  • Colorectal Cancer

Use Indices to:

Harmonize your access strategy with a single source of truth for what and why from a unique blend of Payers, HCPs and Office Managers

Develop actionable strategy with unblinded organization names

Avoid being blindsided by keeping a pulse on the impact of payer trends and market trends from MMIT’s panel representing 75% of Commercial and Medicare lives

Access therapeutic area specific data with the ability to further customize

How can I understand current and anticipated payer management of my brands?



How can I gain visibility into emerging trends for improved competitive positioning?



How are HCP and Practice Manager stakeholders perceiving my brand & competitors?



QUIZ

Test Your Knowledge

Test your knowledge on payer management priorities, unmet need and cost control methods.

PLAYBOOK

Impact of Oncology Biosimilars

Identifying payers that are early biosimilar adopters and likely to prefer biosimilars is mission critical.

SPECIAL REPORT

Value-Based Agreements Between Payers and Manufacturers

How will you prepare your approach to value-based contracting discussions?

Resources for Your Payer Challenges

MMIT offers a variety of payer account and contact intelligence solutions. Learn more about them below.